Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Edan

Showing results (101-110 of 149) with videos related to

Pageof 15
Sort By:
JAMA Neurology|January 22, 2014
Vitamin D as an early predictor of multiple sclerosis activity and progressionAlberto Ascherio, Kassandra L Munger, Rick White, et al.
Archives of Neurology|September 12, 2007
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year resultsFrederik Barkhof, Chris H Polman, Ernst-Wilhelm Radue, et al.
Neurology|April 18, 2020
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFITMarianna Cortese, Kassandra L Munger, Elena H Martínez-Lapiscina, et al.
Archives of Neurology|October 10, 2007
Acute fulminant demyelinating disease: a descriptive study of 60 patientsJérôme de Seze, Marc Debouverie, Hélène Zephir, et al.
Annals of Neurology|July 3, 2003
Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patientsMehdi Alizadeh, Marie-Claude Babron, Brigitte Birebent, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 19, 2018
Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio studyBenoît Combès, Anne Kerbrat, Jean Christophe Ferré, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2018
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trialsDorothea Buck, Till Fm Andlauer, Wilmar Igl, et al.
Annals of Clinical and Translational Neurology|April 8, 2021
Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilament-light chain in multiple sclerosisAudrey Gauthier, Sébastien Viel, Magali Perret, et al.
Neurology|July 1, 2021
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisIzanne Roos, Emmanuelle Leray, Romain Casey, et al.
Brain Imaging and Behavior|August 30, 2018
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometryKerstin Bendfeldt, Bernd Taschler, Laura Gaetano, et al.
Pageof 15

Showing results (101-110 of 149) with videos related to

Sort By:
Pageof 15
JAMA Neurology|January 22, 2014
Vitamin D as an early predictor of multiple sclerosis activity and progressionAlberto Ascherio, Kassandra L Munger, Rick White, et al.
Archives of Neurology|September 12, 2007
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year resultsFrederik Barkhof, Chris H Polman, Ernst-Wilhelm Radue, et al.
Neurology|April 18, 2020
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFITMarianna Cortese, Kassandra L Munger, Elena H Martínez-Lapiscina, et al.
Archives of Neurology|October 10, 2007
Acute fulminant demyelinating disease: a descriptive study of 60 patientsJérôme de Seze, Marc Debouverie, Hélène Zephir, et al.
Annals of Neurology|July 3, 2003
Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patientsMehdi Alizadeh, Marie-Claude Babron, Brigitte Birebent, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 19, 2018
Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio studyBenoît Combès, Anne Kerbrat, Jean Christophe Ferré, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2018
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trialsDorothea Buck, Till Fm Andlauer, Wilmar Igl, et al.
Annals of Clinical and Translational Neurology|April 8, 2021
Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilament-light chain in multiple sclerosisAudrey Gauthier, Sébastien Viel, Magali Perret, et al.
Neurology|July 1, 2021
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisIzanne Roos, Emmanuelle Leray, Romain Casey, et al.
Brain Imaging and Behavior|August 30, 2018
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometryKerstin Bendfeldt, Bernd Taschler, Laura Gaetano, et al.
Pageof 15